65,437 trials
Small Bowel Crohn's Disease
Primary: Percentage of Participants Who Achieved Clinical Remission at Week 24 — 25.0; 25.0; 16.7 percentage of participants
Paroxysmal Atrial Fibrillation
Primary: Local Impedance and Local Impedance Change at Day Zero and PVI Gaps at the Month 3 Assessment — 106.2; 101.9; -19.6; -13.9 ohm
Migraine
Primary: Proportion of Patients With Treatment Discontinuation Due to an Adverse Event (AE) During the Double-blind Treatment Epoch/Period (DBTE) — 41; 151 Participants — p=<.001
Spinal Cord Injury at C4-C6 Level
Primary: Change in Voluntary Movement — 2; 0 Participants
Alzheimers Disease
Primary: Percentage of Participants With Adverse Events (AEs) — 80.0; 75.0; 50.0; 83.3 Percentage of Participants
Molluscum Contagiosum
Primary: The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following…
Breast Cancer
Primary: The Gain in Imagio IUS Alone Specificity vs Imagio (IUS+OA) Specificity at Fixed 95-99% Sensitivity (fSp), Cohort 1 — 80.9; 75.4; 78.7; 71.4 Percent of correct benign…
Diabetes
Primary: HbA1c at Three Months of Each Period of Treatment — 10.7; 11.2; 7.8; 7.3 percentage (DCCT unit)
Cataract
Primary: Residual Refractive Cylinder — 0.02 diopters
Advance Care Planning
Primary: Number of Patient's Documented Advance Care Planning Discussion- Nurse Navigator — 134; 0 Discussions
Adenoid Cystic Carcinoma
Primary: Best Overall Response Rate — 0; 0; 11; 5 Participants
Cannabis Use Disorder
Primary: Time to Cannabis Use Relapse — 1; 1 days
Heart Failure
Primary: Number of Patients Free From Major Adverse Cardiac and Neurological Events (MACNE) at 6 Weeks. — 51 Participants
Opioid Safety · Prescription Opioid Misuse · Chronic Pain
Primary: Current Opioid Misuse Measure (COMM) — 11.3; 11.9; 9.4; 9.5 score on a scale — p=<0.05
Breast Cancer
Primary: Residual Motion During Deep Inspiratory Breath-Hold (DIBH) — 0.27; 0.27 mm